experiments in this section compound of formula i was used as unsolvated form 1 compound of formula i produced dose dependant inhibition of lung eosinophilia in this model after dosing as an intra tracheal it suspension in saline 30 min prior to ovalbumin challenge significant inhibition is achieved after a single dose of 30 u03bcg of compound of formula i and the response was significantly p 0 016 greater than that seen with an equivalent dose of fluticasone propionate in the same study 69 inhibition with compound of formula i vs 41 inhibition with fluticasone propionate in a rat model of thymus involution 3 daily it doses of 100 u03bcg of compound i induced significantly smaller reductions in thymus weight p 0 004 than an equivalent dose of fluticasone propionate in the same study 67 reduction of thymus weight with compound i vs 78 reduction with fluticasone propionate taken together these results indicate a superior therapeutic index for compound i compared to fluticasone propionate incubation of compound i with rat or human hepatocytes shows the compound to be metabolised in an identical manner to fluticasone propionate with the 17 u03b2 carboxylic acid x being the only significant metabolite produced investigation of the rate of appearance of.